Clinical Data, Inc. Strengthens PGxHealth(TM) Leadership with Key Industry Hires.Meeta Patnaik, MD, Appointed as SVP SVP S'il Vous Plaît (French: Please) SVP Senior Vice President SVP Schweizerische Volkspartei (Swiss People~s Party) SVP Society of Vertebrate Paleontology SVP Social Venture Partners SVP St Vincent de Paul of Predictive Diagnostics Development and Marcia Lewis, PhD, as VP of Biomarker Development NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CLDA CLDA California Lyme Disease Association ), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, today announced the PGxHeath[TM] divisional appointments of Meeta Patnaik, MD, as Senior Vice President of Predictive Diagnostics Development and Marcia Lewis, Ph.D., as Vice President of Biomarker Development. Drew Fromkin, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Clinical Data, said, "I am excited to have Drs. Patnaik and Lewis join Clinical Data. Both are exceptional individuals who are well-established and experienced in their respective fields of diagnostics and biomarker development. They will be instrumental in strengthening Clinical Data's ability to tap the commercial value of our growing biomarker intellectual property." Dr. Meeta Patnaik was most recently the Chief Medical Officer of Lipomics Technologies where she was responsible for developing a diagnostic program to enable and support all phases of pharmaceutical drug development programs and diagnostic commercialization of proprietary assets. Patnaik was a founder of Pathway Diagnostics where she was the Senior Vice President and Chief Science and Technology Officer, and was responsible for the development and commercialization of new diagnostic assays. Prior to Pathway Diagnostics, Patnaik held various senior scientific and leadership positions worldwide at Specialty Labs and established laboratories in India, Egypt, Malaysia and Singapore. Dr. Patnaik received her MD from SCB Medical College in India and has held academic positions at various universities, including California State University, Dominguez Hills California State University, Dominguez Hills (CSUDH) is a campus of the California State University system. It is located in the Los Angeles suburb of Carson, California. and the Department of Biotechnology The Centre for Biotechnology at Acharya Nagarjuna University was established in year 1994 inaugurated by the then Secretary, Department of Biotechnology, Government of India, Dr.C.R.Bhatia. The centre was offering two academic programs, M.Sc. (Biotechnology) and M.Tech. , Microbiology and Immunology, University of California, Los Angeles UCLA comprises the College of Letters and Science (the primary undergraduate college), seven professional schools, and five professional Health Science schools. Since 2001, UCLA has enrolled over 33,000 total students, and that number is steadily rising. . Patnaik is also the author of over 70 published scientific papers and journal articles and has presented at a number of professional and academic institutions worldwide. Marcia Lewis, Ph.D. was most recently the Senior Director of Oncology Programs at Celera (NYSE NYSE See: New York Stock Exchange : CRA See Community Reinvestment Act. ) where she focused on the identification and validation of diagnostic biomarkers for oncology discovered via Celera's proprietary proteomics platform. While at Celera, she represented the company on the Biomarker Working Group for the Pharmaceutical Research and Manufacturers of America Pharmaceutical Research and Manufacturers of America (PhRMA) is an industry trade group representing the pharmaceutical research and biotechnology companies in the United States. (PhRMA). Prior to Celera, Dr. Lewis spent 13 years at Bayer Diagnostics in various positions including that of Director of Genomics and Bioinformatics, Program Manager of the Colorectal Cancer Program, and Project Manager of Nucleic Acid Diagnostics and Corporate Research. She also served on the Board of Directors of the SNP Consortium where she represented the Bayer AG organization. Dr. Lewis has a B.S. from Cornell University in Biological Sciences. She has an M.S. in Microbiology from the University of Georgia Organization The President of the University of Georgia (as of 2007, Michael F. Adams) is the head administrator and is appointed and overseen by the Georgia Board of Regents. and a Ph.D. from the University of Alberta in Basic Medical Sciences (Neurovirology); she also completed a postdoctoral fellowship at Yale University School of Medicine. Dr. Lewis has been an invited speaker at many biomarker meetings and currently serves on the editorial board of Biomarkers in Medicine. About Clinical Data, Inc. Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare(TM). Its PGxHealth(TM) division focuses on proprietary biomarker and pharmacogenetic test development as well as targeted therapeutics to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics(TM) division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Visit the company's website at www.clda.com for more information. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion